Abbas Montazeri

Abbas Montazeri

Auto-generated profile, based on publicly available information

Abbas Montazeri

Computational Nanomaterials Lab (CNL), Faculty of Materials Science and Engineering, K. N. Toosi University of Technology, Tehran, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2013 in Nano Letters
Verified
Journal Article
Closed access
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi
SLSamuel E. Lohse
Samuel E. Lohse
CMCatherine J. Murphy
Catherine J. Murphy
AFArman Fathizadeh
Arman Fathizadeh
AMAbbas Montazeri
Abbas Montazeri
KSKenneth Suslick
Kenneth Suslick

1 October 2011 in Physics Letters A
Verified
Journal Article
Closed access
AMA. Montazeri
A. Montazeri
HRH. Rafii-Tabar
H. Rafii-Tabar

8 March 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
MTMahdi Tavakol
Mahdi Tavakol
AMAbbas Montazeri
Abbas Montazeri
RNReza Naghdabadi
Reza Naghdabadi
MHMohammad J. Hajipour
Mohammad J. Hajipour
SZSaeid Zanganeh
Saeid Zanganeh
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi
Once in biological fluids, the surface of nanoparticles (NPs) is rapidly covered with a layer of biomolecules (i.e., the “protein corona”) whose composition strongly determines their biological identity, regulates interactions with biological entities including cells and the immune system, and consequently directs the biological fate and pharmacokinetics of nanoparticles. We recently introduced the concept of a “personalized protein corona” which refers to the formation of different biological identities of the exact same type of NP after being exposed to extract plasmas from individuals who have various types of diseases. As different diseases have distinct metabolomic profiles and metabolites can interact with proteins, it is legitimate to hypothesize that metabolomic profiles in plasma may have the capacity to, at least partially, drive the formation of a personalized protein corona. To test this hypothesis, we employed a multi-scale approach composed of coarse-grained (CG) and all atom (AA) molecular dynamics (MD) simulations to probe the role of glucose and cholesterol (model metabolites in diabetes and hypercholesterolemia patients) in the interaction of fibrinogen protein and polystyrene NPs. Our results revealed that glucose and cholesterol had the capacity to induce substantial changes in the binding site of fibrinogen to the surface of NPs. More specifically, the simulation results demonstrated that increasing the metabolite amount could change the profiles of fibrinogen adsorption and replacement, what is known as the Vroman effect, on the NP surface. In addition, we also found out that metabolites can substantially determine the immune triggering potency of the fibrinogen–NP complex. Our proof-of-concept outcomes further emphasize the need for the development of patient-specific NPs in a disease type-specific manner for high yielding and safe clinical applications.


1 September 2011 in Solid State Communications
Verified
Journal Article
Closed access
RAReza Ansari
Reza Ansari
BMB. Motevalli
B. Motevalli
AMA. Montazeri
A. Montazeri
Shahram AjoriShahram Ajori
Shahram Ajori

1 February 2016 in Materials & Design
Verified
Journal Article
Closed access
SBS. Bashirvand
S. Bashirvand
AMA. Montazeri
A. Montazeri